GD2‐directed CAR‐T cells in combination with HGF‐targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma

Abstract

Ewing sarcoma (EWS) is the second most common and aggressive type of metastatic bone tumor in adolescents and young adults. There is unmet medical need to develop and test novel pharmacological targets and novel therapies to treat EWS. Here, we found that EWS expresses high levels of a p53 isoform, delta133p53. We further determined that aberrant expression of delta133p53 induced HGF secretion resulting in tumor growth and metastasis. Thereafter, we evaluated targeting EWS tumors with HGF receptor neutralizing antibody (AMG102) in preclinical studies. Surprisingly, we found that targeting EWS tumors with HGF receptor neutralizing antibody (AMG102) in combination with GD2‐specific, CAR‐reengineered T‐cell therapy synergistically inhibited primary tumor growth and establishment of metastatic disease in preclinical models. Furthermore, our data suggested that AMG102 treatment alone might increase leukocyte infiltration including efficient CAR‐T access into tumor mass and thereby improves its antitumor activity. Together, our findings warrant the development of novel CAR‐T‐cell therapies that incorporate HGF receptor neutralizing antibody to improve therapeutic potency, not only in EWS but also in tumors with aberrant activation of the HGF/c‐MET pathway.

Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer

“…IHC was performed as described in ref. 19 . Briefly, 4-μm-thick tissue sections were deparaffinized with xylene, rehydrated with descending alcohol series followed by antigen retrieval in citrate buffer.…”

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

“…The first study ( ClinicalTrials.gov Identifier NCT04099797) is scheduled to enroll 34 pediatric patients with high-grade GD2-expressing gliomas or diffuse intrinsic pontine gliomas, whereas the second study ( ClinicalTrials.gov Identifier NCT03252171) has enrolled 60 adult patients with GD2-positive gliomas. Anti-GD2 CAR-T cells have also been studied in GD2-expressing Ewing sarcoma ( 109 ), glioblastoma ( 56 ), and retinoblastoma ( 62 ) and are being studied in osteosarcoma ( ClinicalTrials.gov Identifier NCT02107963). Brown and Gargett are conducting a phase I study in Australia of the safety and immune effects of an escalating dose of autologous GD2 CAR-T cells in patients with GD2-expressing metastatic melanoma ( 110 ).…”

Molecular and Cellular Factors Associated with Racial Disparity in Breast Cancer

“…Tumor suppressor gene p53 is a well-known for its role in DNA repair and inducing apoptosis [ 86 , 87 ]. In most human carcinomas, p53 gets mutated, and its mutational status is also an independent prognostic marker of AA breast cancer [ 88 , 89 ]. Breast cancer mitogen insulin-like growth factor 1 (IGF-1) levels increase in AA women after multiple pregnancies and promote breast cancer progression [ 90 ].…”